3rd December 2015 – Airedale patients test whether aspirin stops cancer returning

Posted on December 4, 2015 by AireAdmin

Patients from Airedale Hospital are taking in the world’s largest ever clinical trial looking at whether taking aspirin can stop some of the most common cancer coming back.

The Add-Aspirin phase III trial, funded by Cancer Research UK and the National Institute for Health Research, aims to find out if taking aspirin every day for five years can stop of delay cancers that have been caught and treated at an early stage from returning. It will also study how the drug might do this.

Airedale is one of 150 centres taking part in the study in the UK and will be looking to recruit around 30 patients a year who have had early stage breast, bowel or prostate cancers. Other centres across the UK will also be recruiting patients with gastro-oesophageal cancer. Around 11,000 patients will be recruited and the trial will run for up to 12 years until 2021.

Carole Paley, head of research and innovation at Airedale NHS Foundation Trust, said patients are recruited by staff screening patients and those who are eligible will be asked to take part in the trial.

She said: “This is a really exciting trial. There is some evidence to suggest that Aspirin might be effective in stopping cancers coming back and we are really pleased to be able to give our patients at Airedale the chance to take part in this important study.

“Unless you are on the trial, it’s important not to start taking aspirin as it isn’t suitable for everyone, and it can have serious side effects. Please speak to your oncologists or research nurse if you would like to join the trial.”

Aspirin is already proven to help prevent heart attacks and strokes in some people, and research has suggested that it could also prevent some types of cancer. The study will compare two groups of people taking different doses of aspirin and a group taking placebo (dummy) tablets.

Professor Ruth Langley, chief investigator from the Medical Research Council Clinical Trials Unit at University College London, said: “There’s been some interesting research suggesting that aspirin could delay or or stop early stage cancers coming back, but there;’s been no randomised trial to give clear proof. This trial aims to answer this question once and for all. If we find that aspirin does stop these cancers returning, it could change future treatment – providing a cheap and simple way to help stop cancer coming back and helping more people survive.”

For more information about the trial call 0808 800 4040 to speak to Cancer Research UK’s information nurses or visit¬†www.cancerhelp.org.uk